Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This 8 weeks, prospective, single center, randomized, open-label, parallel-group,
non-inferiority study was performed from October 2015 to April 2018. This study as designed
to evaluate the efficacy and safety of 10mg of the generic formulation (rosuvastatin,
ROVASRO®) compared to the reference formulation (rosuvastatin, CRESTOR®) in patients with
primary hypercholesterolemia and complex dyslipidemia.